| Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ... Circulation 129 (3), e28-e292, 2014 | 8084* | 2014 |
| 2013 ESC guidelines on the management of stable coronary artery disease G Montalescot, U Sechtem, S Achenbach, F Andreotti, C Arden, A Budaj, ... Türk Kardiyoloji Derneği Arşivi 42, 73-134, 2014 | 5408* | 2014 |
| 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Task Force Members, G Montalescot, U Sechtem, S Achenbach, ... European heart journal 34 (38), 2949-3003, 2013 | 5408 | 2013 |
| 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Task Force Members, G Montalescot, U Sechtem, S Achenbach, ... European heart journal 34 (38), 2949-3003, 2013 | 5405 | 2013 |
| Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study JP Collet, JS Hulot, A Pena, E Villard, JB Esteve, J Silvain, L Payot, ... The Lancet 373 (9660), 309-317, 2009 | 1245 | 2009 |
| Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects JS Hulot, A Bura, E Villard, M Azizi, V Remones, C Goyenvalle, M Aiach, ... Blood 108 (7), 2244-2247, 2006 | 1237 | 2006 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update SA Scott, K Sangkuhl, CM Stein, JS Hulot, JL Mega, DM Roden, TE Klein, ... Clinical Pharmacology & Therapeutics 94 (3), 317-323, 2013 | 1010 | 2013 |
| Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial P Lechat, JS Hulot, S Escolano, A Mallet, A Leizorovicz, ... Circulation 103 (10), 1428-1433, 2001 | 687 | 2001 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy SA Scott, K Sangkuhl, EE Gardner, CM Stein, JS Hulot, JA Johnson, ... CliniCal pharmaCology & TherapeuTiCs 90 (2), 328-332, 2011 | 570 | 2011 |
| Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy JS Hulot, X Jouven, JP Empana, R Frank, G Fontaine Circulation 110 (14), 1879-1884, 2004 | 569 | 2004 |
| Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19* 2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta … JS Hulot, JP Collet, J Silvain, A Pena, A Bellemain-Appaix, O Barthélémy, ... Journal of the American College of Cardiology 56 (2), 134-143, 2010 | 522 | 2010 |
| Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial KT Ong, J Perdu, J De Backer, E Bozec, P Collignon, J Emmerich, ... The Lancet 376 (9751), 1476-1484, 2010 | 385 | 2010 |
| Feasibility and safety of ultrasound-aided thoracentesis in mechanically ventilated patients D Lichtenstein, JS Hulot, A Rabiller, I Tostivint, G Mezière Intensive care medicine 25 (9), 955-958, 1999 | 359 | 1999 |
| Statin therapy is associated with lower prevalence of gut microbiota dysbiosis S Vieira-Silva, G Falony, E Belda, T Nielsen, J Aron-Wisnewsky, ... Nature 581 (7808), 310-315, 2020 | 327 | 2020 |
| Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus N Costedoat‐Chalumeau, Z Amoura, JS Hulot, HA Hammoud, G Aymard, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2006 | 327 | 2006 |
| Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the H eart F ailure A ssociation (HFA), the E uropean A … J Čelutkienė, R Pudil, T López‐Fernández, J Grapsa, P Nihoyannopoulos, ... European journal of heart failure 22 (9), 1504-1524, 2020 | 320 | 2020 |
| Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy H Izzedine, JS Hulot, E Villard, C Goyenvalle, S Dominguez, J Ghosn, ... The Journal of infectious diseases 194 (11), 1481-1491, 2006 | 306 | 2006 |
| Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies H Izzedine, JS Hulot, V Launay-Vacher, P Marcellini, SJ Hadziyannis, ... Kidney International 66 (3), 1153-1158, 2004 | 279 | 2004 |
| Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis I Abi Nasr, A Bouzamondo, JS Hulot, O Dubourg, JY Le Heuzey, P Lechat European heart journal 28 (4), 457-462, 2007 | 268 | 2007 |
| Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis G Cayla, JS Hulot, SA O’Connor, A Pathak, SA Scott, Y Gruel, J Silvain, ... Jama 306 (16), 1765-1774, 2011 | 265 | 2011 |
